BMJ12h
AB0860 STUDY DESIGN OF ROCCELLA: A PHASE 2 CLINICAL TRIAL WITH A DISEASE-MODIFYING OSTEOARTHRITIS DRUG CANDIDATE GLPG1972/S201086
Background: Loss of articular cartilage is one of the major signs of osteoarthritis (OA). Aggrecan, the main proteoglycan component of the extracellular matrix of articular cartilage is cleaved by ...
BMJ14h
PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes
Correspondence to Dr. Nunzio Bottini, Dept. of Medicine, University of California San Diego, MC0656, La Jolla, CA 92093, USA; nbottini{at}ucsd.edu; Professor Costantino Pitzalis, William Harvey ...
BMJ2d
Long-term outcome in polymyositis and dermatomyositis
1 Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands 2 Department of Neurology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ2d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
BMJ5d
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era
Correspondence to Ping-Hsuan Hsieh, Health Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow G12 8RZ, UK; p.hsieh.1{at}research.gla.ac.uk ...
BMJ5d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...